Although new treatments can prolong progression-free and overall survival in patients with renal cell carcinoma (RCC), the cure rate remains low and surgical resection of the primary tumor and metastases are still the most important treatment options to eliminate RCC or achieve long-term progression-free survival.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Alt, A. L. et al. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer doi: 10.1002/cncr.25836.
Motzer, R. J. et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J. Clin. Oncol. 22, 454–463 (2004).
Heng, D. Y. et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J. Clin. Oncol. 27, 5794–5799 (2009).
Winter, H. et al. Tumor infiltrated hilar and mediastinal lymph nodes are an independent prognostic factor for decreased survival after pulmonary metastasectomy in patients with renal cell carcinoma. J. Urol. 184, 1888–1894 (2010).
Fottner, A. et al. Bone metastases from renal cell carcinoma: patient survival after surgical treatment. BMC Musculoskelet. Disord. 11, 145 (2010).
Karam, J. A. et al. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J. Urol. 185, 439–444 (2011).
Staehler, M. D. et al. Liver resection for metastatic disease prolongs survival in renal cell carcinoma: 12-year results from a retrospective comparative analysis. World J. Urol. 28, 543–547 (2010).
Ebos, J. M., Lee, C. R., Christensen, J. G., Mutsaers, A. J. & Kerbel, R. S. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc. Natl Acad. Sci. USA 104, 17069–17074 (2007).
Johannsen, M. et al. Outcome of treatment discontinuation in patients with metastatic renal cell carcinoma and no evidence of disease following targeted therapy with or without metastasectomy. Ann. Oncol. 22, 657–663 (2010).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The authors declares that he acts as a consultant and speaker/honoraria for the following companies: Bayer, GlaxoSmithKline, Novartis, Pfizer and Roche.
Rights and permissions
About this article
Cite this article
Staehler, M. The role of metastasectomy in metastatic renal cell carcinoma. Nat Rev Urol 8, 180–181 (2011). https://doi.org/10.1038/nrurol.2011.30
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2011.30
This article is cited by
-
Oncological outcomes after cytoreductive nephrectomy for patients with metastatic renal cell carcinoma with inferior vena caval tumor thrombus
International Journal of Clinical Oncology (2018)
-
Time-dependent change in relapse sites of renal cell carcinoma after curative surgery
Clinical & Experimental Metastasis (2018)
-
Differential expression and clinical relevance of MUC1 in renal cell carcinoma metastasis
World Journal of Urology (2016)
-
Lungenmetastasen und Ansatzpunkte der chirurgischen Therapie
Der Onkologe (2015)
-
Role of metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy
World Journal of Urology (2014)
